Needham Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Day One Biopharmaceutical (NASDAQ:DAWN) but lowers the price target from $33 to $32.
July 31, 2024 | 9:30 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Day One Biopharmaceutical but lowers the price target from $33 to $32.
The analyst's decision to maintain a Buy rating is positive, but the slight reduction in the price target may indicate some caution. Overall, the impact on the stock price is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100